Core Viewpoint - WuXi AppTec has announced the sale of its clinical service subsidiaries, aiming to focus on its CRDMO business model and enhance global capabilities while reporting strong financial performance in the first three quarters of the year [1][2][9]. Group 1: Asset Sale Details - WuXi AppTec plans to sell 100% equity of its subsidiaries, Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jishi Pharmaceutical Technology Co., Ltd., to Hillhouse Capital for a base price of 2.8 billion yuan [1]. - The two subsidiaries generated approximately 1.16 billion yuan in revenue and 90 million yuan in net profit for the first three quarters of 2025, accounting for 3.5% and 0.7% of WuXi AppTec's total revenue and net profit, respectively [2]. Group 2: Strategic Focus - The sale is part of WuXi AppTec's strategy to concentrate on its CRDMO business model, which includes drug discovery, laboratory testing, and process development, thereby providing financial support for global capacity expansion [2][7]. - The company has been optimizing its business structure over the past year, including the sale of its WuXi ATU business in the U.S. and U.K., which contributed 1.32 billion yuan in revenue for 2024 [3]. Group 3: Financial Performance - For the first three quarters of 2025, WuXi AppTec reported revenue of 32.857 billion yuan, a year-on-year increase of 18.61%, and a net profit of 12.076 billion yuan, up 84.84% [9]. - The chemical segment was the largest revenue contributor, generating 25.98 billion yuan, a 29.3% increase year-on-year [10]. - The U.S. market remains the primary revenue source, with 22.15 billion yuan in revenue, reflecting a 31.9% growth [11].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 WUXI BIOLOGICS (CAYMAN) INC. 藥明生物技術有限公司* 於晚上八時正（香港時間）以英文進行的電話會議： https://jefferies.zoom.us/webinar/register/WN_A74otDPyQciXKWgDXMAwCA 請在電話會議進行前使用上文提供的鏈接完成線上註冊程序。 （於開曼群島註冊成立的有限公司） （股份代號：2269） 內幕消息 二零二五年中期業績簡報 本公告由WuXi Biologics (Cayman) Inc.藥明生物技術有限公司*（「本公司」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章《證券及期貨條例》第XIVA部項下內幕消息條文（定義見上市規則）而作出。 為使本公司股東及潛在投資者能夠更深入、更全面地了解其二零二五年中期 業績及業務營運，本公司將於二零二五年八月二十日上午九時正及晚上八時 ...